Table 4. Secondary outcomes.
| Treatment group | |||
| Category. | Quinine (n = 111) | AL (n = 35) | DHAPQ (n = 72) |
| Fever clearance * | |||
| - Fever on day 1§ | 65 (58.6%) | 14 (40.0%) | 48 (66.7%) |
| - Fever on day 2 | 33 (29.7%) | 21 (20.0%) | 15 (20.8%) |
| - Fever on day 3 | 5 (4.5% | 2 (5.7%) | 4 (5.6%) |
| Parasite clearance | |||
| - Parasitemia on day 2± ∥ § | 56 (50.5%) | 5 (14.3%) | 2 (2.8%) |
| - Parasitemia on day 3 | 2 (1.8%) | 0 (0.0%) | 0 (0.0%) |
| a Appearance of gametocytes not present on day 0 | |||
| - Days 1–28 | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) |
| Hemoglobin (Hb) recovery † | |||
| - Mean increase (SD) in Hb (g/dL) | 1.08 (1.4) | 0.93 (1.7) | 0.80 (1.7) |
| Adverse events days 1–28 | |||
| Cough | 67 (60.4%) | 20 (57.1%) | 47 (65.3%) |
| Abdominal pain∥ § | 0 (0.0%) | 0 (0.0%) | 5 (2.0%) |
| Anorexia | 13 (11.7%) | 3 (8.6%) | 12 (16.7%) |
| Vomiting | 1 (0.9%) | 2 (5.7%) | 3 (4.2%) |
| Weakness/malaise | 4 (3.6%) | 0 (0.0%) | 1 (1.4%) |
| Diarrhoea | 11 (9.9%) | 2 (5.7%) | 1 (1.4%) |
| Serious adverse event | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) |
*
Subjective fever over previous 24 hours or temperature ≥37.5°C.
†
Change in Hb from day 0 to day 28 or day of clinical failure.
a
Patients with gametocytes present on day 0 not included.
±
Quinine vs AL, p<0.05.
∥
Quinine vs DHAPQ, p<0.05.
§
AL vs DHAPQ, p<0.05.